Last reviewed · How we verify
Adempas
At a glance
| Generic name | Adempas |
|---|---|
| Also known as | Riociguat |
| Sponsor | University of Colorado, Denver |
| Target | Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
Common side effects
- Headache
- Dyspepsia and Gastritis
- Dizziness
- Nausea
- Diarrhea
- Hypotension
- Vomiting
- Anemia
- Gastroesophageal reflux disease
- Constipation
- Palpitations
- Nasal congestion
Serious adverse events
- Embryo-Fetal Toxicity
- Hypotension
- Bleeding
Key clinical trials
- Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty (PHASE2)
- Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
- Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH (PHASE2)
- A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy (PHASE4)
- Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH (PHASE3)
- A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (PHASE4)
- Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adempas CI brief — competitive landscape report
- Adempas updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI